Autoantibodies targeting tumor-associated antigens in metastatic cancer Sialylated iggs as candidate anti-inflammatory antibodies

OncoImmunology

Volumn 2, Issue 6, 2013, Pages

  Oaks, Martin ^a   Taylor, Samuel ^a   Shaffer, James ^a  

^a ST LUKE S MEDICAL CENTER   (United States)

Author keywords

Anti inflammatory; DC SIGN; Glycosylation; HER 2 neu; IgG; NY ESO 1; Sialic acid; Tumor immunity

Indexed keywords

AGGLUTININ; ALPHA 2,6 SIALIC ACID; ANTIBODY; ANTIINFLAMMATORY ANTIBODY; AUTOANTIBODY; CD209 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; GLYCAN DERIVATIVE; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; INTERCELLULAR ADHESION MOLECULE 2; INTERCELLULAR ADHESION MOLECULE 3; NY ESO 1 ANTIGEN; SAMBUCUS NIGRA AGGLUTININ; SIALIC ACID; SIALYLTRANSFERASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BREAST CARCINOMA; BREAST METASTASIS; CANCER GROWTH; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; METASTATIC MELANOMA; MOLECULAR DYNAMICS; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; SIALYLATION; TUMOR ESCAPE; TUMOR GROWTH;

EID: 84886945075     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.24841     Document Type: Article

References (63)

1. Sahin U, Türeci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A 1995; 92:11810-3; PMID:8524854; http://dx.doi.org/10.1073/pnas.92.25.11810
2. Reuschenbach M, von Knebel Doeberitz M, Wentzensen N. A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother 2009; 58:1535-44; PMID:19562338; http://dx.doi. org/10.1007/s00262-009-0733-4
3. Kobold S, Lütkens T, Cao Y, Bokemeyer C, Atanackovic D. Autoantibodies against tumor-related antigens: incidence and biologic significance. Hum Immunol 2010; 71:643-51; PMID:20433885; http://dx.doi.org/10.1016/j.humimm.2010.03.015
4. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; http://dx.doi.org/10.1126/science. 1203486
5. Radoja S, Rao TD, Hillman D, Frey AB. Mice bearing late-stage tumors have normal functional systemic T cell responses in vitro and in vivo. J Immunol 2000; 164:2619-28; PMID:10679101
6. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29:235-71; PMID:21219185; http://dx.doi.org/10.1146/annurevimmunol- 031210-101324
7. Wei S, Curiel T, Coukos G, Liu R, Zou W. Inhibitory B7 family members in human ovarian carcinoma. Adv Exp Med Biol 2008; 622:261-71; PMID:18546634; http://dx.doi.org/10.1007/978-0-387-68969-2_21
8. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008; 8:467-77; PMID:18500231; http://dx.doi. org/10.1038/nri2326
9. Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010; 116:1757-66; PMID:20143437; http://dx.doi.org/10.1002/cncr.24899
10. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 2007; 25:21-50; PMID:17029568; http://dx.doi.org/10.1146/annurev. immunol.25.022106.141702
11. Hodoniczky J, Zheng YZ, James DC. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog 2005; 21:1644-52; PMID:16321047; http://dx.doi. org/10.1021/bp050228w
12. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277:26733-40; PMID:11986321; http://dx.doi.org/10.1074/jbc. M202069200
13. Satoh M, Iida S, Shitara K. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin Biol Ther 2006; 6:1161-73; PMID:17049014; http://dx.doi. org/10.1517/14712598.6.11.1161
14. Kaneko Y, Nimmerjahn F, Ravetch JV. Antiinflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313:670-3; PMID:16888140; http://dx.doi.org/10.1126/science. 1129594
15. Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 2007; 44:1524-34; PMID:17045339; http://dx.doi.org/10.1016/j.molimm.2006.09.005
16. Anthony RM, Kobayashi T, Wermeling F, Ravetch JV. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 2011; 475:110-3; PMID:21685887; http://dx.doi. org/10.1038/nature10134
17. Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identification of a receptor required for the antiinflammatory activity of IVIG. Proc Natl Acad Sci U S A 2008; 105:19571-8; PMID:19036920; http://dx.doi.org/10.1073/pnas.0810163105
18. Nimmerjahn F, Ravetch JV. The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med 2007; 204:11-5; PMID:17227911; http://dx.doi. org/10.1084/jem.20061788
19. Anthony RM, Ravetch JV. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol 2010; 30(Suppl 1):S9-14; PMID:20480216; http://dx.doi.org/10.1007/s10875-010-9405-6
20. Anthony RM, Wermeling F, Ravetch JV. Novel roles for the IgG Fc glycan. Ann N Y Acad Sci 2012; 1253:170-80; PMID:22288459; http://dx.doi.org/10.1111/j.1749-6632.2011.06305.x
21. Raju TS, Scallon BJ. Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by papain. Biochem Biophys Res Commun 2006; 341:797-803; PMID:16442075; http://dx.doi.org/10.1016/j. bbrc.2006.01.030
22. Stadlmann J, Pabst M, Kolarich D, Kunert R, Altmann F. Analysis of immunoglobulin glycosylation by LC-ESI-MS of glycopeptides and oligosaccharides. Proteomics 2008; 8:2858-71; PMID:18655055; http://dx.doi.org/10.1002/pmic.200700968
23. Stadlmann J, Weber A, Pabst M, Anderle H, Kunert R, Ehrlich HJ, et al. A close look at human IgG sialylation and subclass distribution after lectin fractionation. Proteomics 2009; 9:4143-53; PMID:19688751; http://dx.doi.org/10.1002/pmic.200800931
24. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA. High-titer HER-2/neu protein-specific antibody can be detected in patients with earlystage breast cancer. J Clin Oncol 1997; 15:3363-7; PMID:9363867
25. Goodell V, Waisman J, Salazar LG, de la Rosa C, Link J, Coveler AL, et al. Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. Mol Cancer Ther 2008; 7:449-54; PMID:18319334; http://dx.doi.org/10.1158/1535-7163.MCT-07-0386
26. Chapman CJ, Murray A, McElveen JE, Sahin U, Luxemburger U, Türeci O, et al. Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax 2008; 63:228-33; PMID:17932110; http://dx.doi.org/10.1136/thx.2007.083592
27. Stockert E, Jäger E, Chen YT, Scanlan MJ, Gout I, Karbach J, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998; 187:1349-54; PMID:9547346; http://dx.doi.org/10.1084/jem.187.8.1349
28. Ward RL, Hawkins NJ, Coomber D, Disis ML. Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer. Hum Immunol 1999; 60:510-5; PMID:10408800; http://dx.doi. org/10.1016/S0198-8859(99)00003-8
29. Montgomery RB, Makary E, Schiffman K, Goodell V, Disis ML. Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase. Cancer Res 2005; 65:650-6; PMID:15695410
30. van Rhee F, Szmania SM, Zhan F, Gupta SK, Pomtree M, Lin P, et al. NY-ESO-1 is highly expressed in poorprognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 2005; 105:3939-44; PMID:15671442; http://dx.doi. org/10.1182/blood-2004-09-3707
31. Zeng G, Aldridge ME, Wang Y, Pantuck AJ, Wang AY, Liu YX, et al. Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: implications as a potential biomarker. Int J Cancer 2005; 114:268-73; PMID:15540228; http://dx.doi.org/10.1002/ijc.20716
32. Akcakanat A, Kanda T, Koyama Y, Watanabe M, Kimura E, Yoshida Y, et al. NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer. Cancer Chemother Pharmacol 2004; 54:95-100; PMID:15118836; http://dx.doi.org/10.1007/s00280-004-0768-3
33. Akcakanat A, Kanda T, Tanabe T, Komukai S, Yajima K, Nakagawa S, et al. Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: Implications for immunotherapy. Int J Cancer 2006; 118:123-8; PMID:16003736; http://dx.doi.org/10.1002/ijc.21219
34. Türeci O, Mack U, Luxemburger U, Heinen H, Krummenauer F, Sester M, et al. Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. Cancer Lett 2006; 236:64-71; PMID:15992994; http://dx.doi.org/10.1016/j.canlet. 2005.05.008
35. Korangy F, Ormandy LA, Bleck JS, Klempnauer J, Wilkens L, Manns MP, et al. Spontaneous tumorspecific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res 2004; 10:4332-41; PMID:15240519; http://dx.doi.org/10.1158/1078-0432.CCR-04-0181
36. Nakamura S, Nouso K, Noguchi Y, Higashi T, Ono T, Jungbluth A, et al. Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma. J Gastroenterol Hepatol 2006; 21:1281-5; PMID:16872310; http://dx.doi.org/10.1111/j.1440-1746.2006.04271.x
37. Fosså A, Berner A, Fosså SD, Hernes E, Gaudernack G, Smeland EB. NY-ESO-1 protein expression and humoral immune responses in prostate cancer. Prostate 2004; 59:440-7; PMID:15065093; http://dx.doi. org/10.1002/pros.20025
38. Odunsi K, Jungbluth AA, Stockert E, Qian F, Gnjatic S, Tammela J, et al. NY-ESO-1 and LAGE-1 cancertestis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res 2003; 63:6076-83; PMID:14522938
39. Huhn C, Selman MH, Ruhaak LR, Deelder AM, Wuhrer M. IgG glycosylation analysis. Proteomics 2009; 9:882-913; PMID:19212958; http://dx.doi. org/10.1002/pmic.200800715
40. Kim YJ, Varki A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J 1997; 14:569-76; PMID:9298689; http://dx.doi.org/10.1023/A:1018580324971
41. Varki A, Kannagi R, Toole BP. Glycosylation Changes in Cancer. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Betozzi CR, et al. Essentials of Glycobiology. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 2009:617-32.
42. Kaplan HA, Woloski BM, Hellman M, Jamieson JC. Studies on the effect of inflammation on rat liver and serum sialyltransferase. Evidence that inflammation causes release of Gal beta 1 leads to 4GlcNAc alpha 2 leads to 6 sialyltransferase from liver. J Biol Chem 1983; 258:11505-9; PMID:6413502
43. Käsermann F, Boerema DJ, Rüegsegger M, Hofmann A, Wymann S, Zuercher AW, et al. Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation. PLoS One 2012; 7:e37243; PMID:22675478; http://dx.doi.org/10.1371/journal.pone.0037243
44. Dalziel M, McFarlane I, Axford JS. Lectin analysis of human immunoglobulin G N-glycan sialylation. Glycoconj J 1999; 16:801-7; PMID:11133020; http://dx.doi.org/10.1023/A:1007183915921
45. Stadlmann J, Pabst M, Altmann F. Analytical and Functional Aspects of Antibody Sialylation. J Clin Immunol 2010; In press; PMID:20390325; http://dx.doi.org/10.1007/s10875-010-9409-2
46. Guhr T, Bloem J, Derksen NI, Wuhrer M, Koenderman AH, Aalberse RC, et al. Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia. PLoS One 2011; 6:e21246; PMID:21731683; http://dx.doi.org/10.1371/journal. pone.0021246
47. Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther 2007; 7:1401-13; PMID:17727329; http://dx.doi. org/10.1517/14712598.7.9.1401
48. Holland M, Yagi H, Takahashi N, Kato K, Savage CO, Goodall DM, et al. Differential glycosylation of polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients with ANCA-associated systemic vasculitis. Biochim Biophys Acta 2006; 1760:669-77; PMID:16413679; http://dx.doi.org/10.1016/j.bbagen. 2005.11.021
49. Lastra GC, Thompson SJ, Lemonidis AS, Elson CJ. Changes in the galactose content of IgG during humoral immune responses. Autoimmunity 1998; 28:25-30; PMID:9754811; http://dx.doi. org/10.3109/08916939808993842
50. van de Geijn FE, Wuhrer M, Selman MH, Willemsen SP, de Man YA, Deelder AM, et al. Immunoglobulin G galactosylation and sialylation are associated with pregnancy- induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study. Arthritis Res Ther 2009; 11:R193; PMID:20015375; http://dx.doi.org/10.1186/ar2892
51. Espy C, Morelle W, Kavian N, Grange P, Goulvestre C, Viallon V, et al. Sialylation levels of anti-proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (Wegener's). Arthritis Rheum 2011; 63:2105-15; PMID:21437874; http://dx.doi. org/10.1002/art.30362
52. Scherer HU, van der Woude D, Ioan-Facsinay A, el Bannoudi H, Trouw LA, Wang J, et al. Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis Rheum 2010; 62:1620-9; PMID:20178128; http://dx.doi. org/10.1002/art.27414
53. Saldova R, Royle L, Radcliffe CM, Abd Hamid UM, Evans R, Arnold JN, et al. Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology 2007; 17:1344-56; PMID:17884841; http://dx.doi.org/10.1093/glycob/cwm100
54. Wuhrer M, Porcelijn L, Kapur R, Koeleman CA, Deelder A, de Haas M, et al. Regulated glycosylation patterns of IgG during alloimmune responses against human platelet antigens. J Proteome Res 2009; 8:450-6; PMID:18942870; http://dx.doi.org/10.1021/pr800651j
55. Lux A, Aschermann S, Biburger M, Nimmerjahn F. The pro and anti-inflammatory activities of immunoglobulin G. Ann Rheum Dis 2010; 69(Suppl 1):i92-6; PMID:19995755; http://dx.doi.org/10.1136/ard.2009.117101
56. Katz U, Shoenfeld Y, Zandman-Goddard G. Update on intravenous immunoglobulins (IVIg) mechanisms of action and off-label use in autoimmune diseases. Curr Pharm Des 2011; 17:3166-75; PMID:21864262; http://dx.doi.org/10.2174/138161211798157540
57. Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 2007; 6:257-9; PMID:17317619; http://dx.doi.org/10.1016/j.autrev.2006.08.011
58. Jordan SC, Vo AA, Tyan D, Nast CC, Toyoda M. Current approaches to treatment of antibody-mediated rejection. Pediatr Transplant 2005; 9:408-15; PMID:15910400; http://dx.doi.org/10.1111/j.1399-3046.2005.00363.x
59. Jordan SC, Vo AA, Toyoda M, Tyan D, Nast CC. Post-transplant therapy with high-dose intravenous gammaglobulin: Applications to treatment of antibodymediated rejection. Pediatr Transplant 2005; 9:155-61; PMID:15787786; http://dx.doi.org/10.1111/j.1399-3046.2005.00256.x
60. Jordan SC, Toyoda M, Vo AA. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation 2009; 88:1-6; PMID:19584672; http://dx.doi.org/10.1097/TP.0b013e3181a9e89a
61. Kaneko Y, Nimmerjahn F, Ravetch JV. Antiinflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313:670-3; PMID:16888140; http://dx.doi.org/10.1126/science. 1129594
62. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008; 320:373-6; PMID:18420934; http://dx.doi.org/10.1126/science.1154315
63. Su SV, Hong P, Baik S, Negrete OA, Gurney KB, Lee B. DC-SIGN binds to HIV-1 glycoprotein 120 in a distinct but overlapping fashion compared with ICAM-2 and ICAM-3. J Biol Chem 2004; 279:19122-32; PMID:14970226; http://dx.doi.org/10.1074/jbc. M400184200